Pure MHC LLC and Myrio Announce Collaboration to Research and Develop Targeted Antibody-Based Cancer Therapies

eNewsChannels NEWS: -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer. :: News from eNewsChannels

Related Keywords

Oklahoma ,United States ,University Of Oklahoma ,Texas ,Kris Looney ,William Hildebrand ,Pete Smith ,Emergent Technologies Inc ,University Of Oklahoma Health Science Center ,Myrio Therapeutics Pty Ltd ,Retained Display ,Emergent Technologies ,Chief Scientist William Hildebrand ,Oklahoma Health Science ,